UA108277C2 - Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения - Google Patents

Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения

Info

Publication number
UA108277C2
UA108277C2 UAA201307936A UAA201307936A UA108277C2 UA 108277 C2 UA108277 C2 UA 108277C2 UA A201307936 A UAA201307936 A UA A201307936A UA A201307936 A UAA201307936 A UA A201307936A UA 108277 C2 UA108277 C2 UA 108277C2
Authority
UA
Ukraine
Prior art keywords
valsartan
lercanidipine hydrochloride
production
preparation containing
complex preparation
Prior art date
Application number
UAA201307936A
Other languages
English (en)
Ukrainian (uk)
Inventor
Юн Сік Чун
Су Ах Парк
Ре Сунь Кім
Сун Іл Кім
Цзе Хьон Цзюн
Дун Ку Кім
Йо Рін Кім
Хі Дун Парк
Сеон Цзе Парк
Сунь Хак Лі
Цзюй Хун Кім
Мінь Юнь Цзюн
Original Assignee
Елджі Лайф Саєнсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA108277(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елджі Лайф Саєнсез Лтд. filed Critical Елджі Лайф Саєнсез Лтд.
Publication of UA108277C2 publication Critical patent/UA108277C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтической композиции для профилактики и лечения сердечнососудистой болезни, которая содержит лерканидипина гидрохлорид и валсартан как активные компоненты; и от 5 до 20% массы супердезинтегрирующего агента, выбранного из группы, который сосотоит из кроскармеллозы, кросповидона и натрия крахмалгликолят и их смесей в расчете на общее количество фармацевтически приемлемых наполнителей, где лерканидипина гидрохлорид и валсартан находятся в уединенной друг от друга форме после перемешивания отдельно приготовленных высушенных гранул лерканидипина гидрохлорида и гранул валсартана; а также к способу приготовления указанной композиции.
UAA201307936A 2010-12-09 2011-12-07 Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения UA108277C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
UA108277C2 true UA108277C2 (ru) 2015-04-10

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201307936A UA108277C2 (ru) 2010-12-09 2011-12-07 Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения

Country Status (17)

Country Link
EP (1) EP2648730A4 (ru)
KR (1) KR101414814B1 (ru)
CN (1) CN103249415B (ru)
AR (1) AR084195A1 (ru)
AU (1) AU2011339150B2 (ru)
BR (1) BR112013013415A2 (ru)
CL (1) CL2013001626A1 (ru)
CO (1) CO6721030A2 (ru)
DO (1) DOP2013000115A (ru)
EA (1) EA201390844A1 (ru)
IL (1) IL226449A0 (ru)
MX (1) MX2013005716A (ru)
PE (1) PE20140699A1 (ru)
SG (1) SG190326A1 (ru)
UA (1) UA108277C2 (ru)
UY (1) UY33772A (ru)
WO (1) WO2012077968A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
EP2977048A4 (en) * 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
TWI388345B (zh) * 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
AU2011339150A1 (en) 2013-06-06
AR084195A1 (es) 2013-04-24
CL2013001626A1 (es) 2013-10-04
KR20120089787A (ko) 2012-08-13
EP2648730A4 (en) 2014-08-06
IL226449A0 (en) 2013-07-31
BR112013013415A2 (pt) 2019-09-24
EP2648730A2 (en) 2013-10-16
CN103249415B (zh) 2017-12-12
WO2012077968A3 (en) 2012-07-26
SG190326A1 (en) 2013-06-28
PE20140699A1 (es) 2014-06-13
EA201390844A1 (ru) 2013-11-29
WO2012077968A2 (en) 2012-06-14
CN103249415A (zh) 2013-08-14
CO6721030A2 (es) 2013-07-31
MX2013005716A (es) 2013-06-12
AU2011339150B2 (en) 2015-09-10
UY33772A (es) 2012-07-31
KR101414814B1 (ko) 2014-07-21
DOP2013000115A (es) 2014-07-31

Similar Documents

Publication Publication Date Title
MY173823A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
IN2012DN03312A (ru)
IN2014KN00948A (ru)
IL219437A (en) Converted benzamide histories, processes for their preparation, pharmacological compounds containing them and their use in the preparation of drugs for the treatment of cardiovascular diseases
WO2010092090A3 (en) Novel salts of sitagliptin
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
WO2011157722A3 (en) Solid ivabradine-containing composition
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
UA108277C2 (ru) Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
PH12014502836A1 (en) Medicament form for release of active ingredients
MX2013011884A (es) Composiciones farmaceuticas de liberacion modificada de desvenlafaxina.
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2013054364A3 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
TN2013000212A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
WO2012114352A3 (en) Pharmaceutical compositions of maraviroc and process for the preparation thereof
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
WO2012131412A3 (en) Pharmaceutical composition containing no, process for the preparation and use thereof
WO2011121475A3 (en) Modified release dosage form comprising desvenlafaxine or salts thereof